TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma — BelieveIT-201

Head and Neck Neoplasms Clinical Trial

Official title:
BelieveIT-201: Phase 2, Randomized Open-labeled Trial of TransCon (TC) TLR7/8 Agonist in Combination With Pembrolizumab or With TC IL-2 β/γ, or Pembrolizumab Alone as Neoadjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Status Recruiting

Clinical Trial Summary

The purpose of this trial is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and pembrolizumab given prior to curative intent surgery in treatment of participants with newly diagnosed Stage III/IVA resectable locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). After surgery, participants will receive local standard-of-care treatment and will be followed for safety, efficacy, and survival for up to 2 years. This trial contains a safety run-in to evaluate the safety and tolerability of the two treatment arms: Arm A (TransCon TLR7/8 Agonist plus pembrolizumab) and Arm B (TransCon TLR7/8 Agonist plus TransCon IL-2 β/γ). The safety run-in will be followed by the randomized Phase 2, open-label part of the trial comparing the safety, efficacy and survival of treatment Arm A or Arm B compared to treatment Arm C (pembrolizumab monotherapy).

Clinical Trial Description

This is a randomized, Phase 2, open-label, multicenter trial of TransCon TLR7/8 Agonist in combination with pembrolizumab, TransCon TLR7/8 Agonist in combination with TransCon IL-2 β/γ, or pembrolizumab monotherapy as neoadjuvant therapy in participants with Stage III-IVA resectable LA-HNSCC. This trial starts with a safety run-in of 12 participants, 6 participants each in Arms A (TransCon TLR7/8 Agonist plus pembrolizumab) and B (TransCon TLR7/8 Agonist plus TransCon IL-2 β/γ) randomized 1:1. After completing the safety run-in, 80 participants will be randomized in a 2:2:1 ratio in 3 treatment Arms A, B or C (pembrolizumab monotherapy). Once randomized, participants should begin treatment within 5 calendar days. Participants enrolled after the safety run-in, into the 2:2:1 randomization part of the trial, will be stratified as follows: oropharyngeal HPV p16 positive versus oropharyngeal HPV p16 negative or larynx/hypopharyngeal/oral cavity regardless of HPV p16 status. All participants should receive study drug(s) every 21 days (Q21D) for 2 cycles followed by curative-intent surgery. After surgery, participants may receive standard-of-care treatment in the adjuvant setting, as per investigator's decision and local guidelines. ;

Study Design

Related Conditions & MeSH terms

Carcinoma, Squamous Cell
Head and Neck Neoplasms
Squamous Cell Carcinoma of Head and Neck

Clinical Trial Details

NCT number	NCT05980598
Study type	Interventional
Source	Ascendis Pharma A/S
Contact	Elizabeth Bradley
Phone	+1 (650) 519-7179
Email	elbr@ascendispharma.com
Status	Recruiting
Phase	Phase 2
Start date	September 29, 2023
Completion date	July 30, 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02548377` - Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial	N/A
Active, not recruiting	`NCT02229656` - Olaparib and Radiotherapy in Head and Neck Cancer	Phase 1
Not yet recruiting	`NCT06347185` - Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study	N/A
Not yet recruiting	`NCT06289049` - Heavy Strength Training in Head and Neck Cancer Survivors	Phase 2
Terminated	`NCT02975739` - Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors	N/A
Recruiting	`NCT00982436` - Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer	Phase 1/Phase 2
Completed	`NCT01025518` - DAHANCA 25A: Resistance Training and Dietary Supplements as Intervention for Regaining Muscle Mass Following Radiotherapy in Head and Neck Cancer Patients	N/A
Active, not recruiting	`NCT00248235` - Resistance Exercise Training for the Shoulder and Neck Following Surgery for Head and Neck Cancer	Phase 2/Phase 3
Terminated	`NCT00073450` - Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)	Phase 2
Completed	`NCT00135161` - Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer	Phase 1
Not yet recruiting	`NCT06458517` - Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Mucositis Induced by Radiotherapy, During the Treatment of Head and Neck Cancers	N/A
Completed	`NCT05269342` - Nurse-led Exercise Improves Shoulder Pain, Shoulder Disability, and Quality of Life in Head and Neck Cancer	N/A
Recruiting	`NCT05544136` - A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer	Phase 2
Terminated	`NCT03286972` - PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning
Recruiting	`NCT04435938` - A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck	Phase 2
Recruiting	`NCT03975465` - EMST and Swallowing in Long-Term Survivors of HNCA	N/A
Recruiting	`NCT03678649` - A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC	Phase 2
Completed	`NCT03292250` - Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]	Phase 2
Completed	`NCT06446570` - Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma	Phase 2
Completed	`NCT02284802` - Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy	N/A